tldrdailynews.com logo

Novo Nordisk Faces Legal and Investor Challenges Over Semaglutide Sales and Safety Concerns

1 min read
Source: PR Newswire
Novo Nordisk Faces Legal and Investor Challenges Over Semaglutide Sales and Safety Concerns
Photo: PR Newswire
TL;DR

Novo Nordisk has filed over 130 lawsuits across 40 states to combat illegal marketing and sale of unsafe, non-FDA-approved compounded semaglutide products, which pose serious health risks due to illicit ingredients and misleading claims. The company is actively working to protect patients through legal action, education campaigns, and advocating for stricter enforcement against counterfeit and unapproved drugs.

Topics:businesshealthcare#compounded-semaglutide#fda-warning#healthcare#lawsuits#novo-nordisk#patient-safety
Share this article
  1. Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"  PR Newswire
  2. Wegovy maker Novo hit with investor class action over revenue forecast cut  Reuters
  3. Novo Nordisk faces investor lawsuit over 'false and misleading' semaglutide sales projections  Fierce Pharma
  4. NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors  GlobeNewswire
  5. NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm  Business Wire

Want the full story? Read the original reporting

Read on PR Newswire